Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Rolf Anton Klaasen"'
Autor:
Joseph Sexton, Daniel Aletaha, Eirik Klami Kristianslund, Espen Andre Haavardsholm, Nils Bolstad, Johanna Elin Gehin, Silje Watterdal Syversen, David John Warren, Guro Løvik Goll, Ingrid Jyssum, Rolf Anton Klaasen
Publikováno v:
RMD Open, Vol 10, Iss 4 (2024)
Objectives The objectives of this study are to identify a therapeutic serum level for adalimumab associated with remission and low disease activity in patients with rheumatoid arthritis.Methods Associations between serum adalimumab trough levels and
Externí odkaz:
https://doaj.org/article/f7d775b33b4a44a5b570036de9438788
Autor:
Tomm Bernklev, Eivind Ness-Jensen, Knut Lundin, Kristian Hveem, Lars Petter Jelsness-Jørgensen, Pernilla Lagergren, Nils Bolstad, David J Warren, Polina Lukina, Ina Lervåg Andersen, Petter Tinbod Eggen, Patricia Gjertrud Mjønes, Elin Rønne, Rolf Anton Klaasen, Rasmus Iversen, Lise Pedersen, Iris Jonkers, Ludvig Magne Sollid
Publikováno v:
BMJ Open, Vol 14, Iss 1 (2024)
Purpose Coeliac disease (CD) is a common disorder and affects about 1% of the population worldwide. CD in the Trøndelag Health Study (HUNT) is a population-based cohort study which was established to provide new knowledge about CD that can improve t
Externí odkaz:
https://doaj.org/article/0bcbf4b973664f5b9c290bbd070de7ee
Autor:
Nils Tore Vethe, Marte Theie Gustavsen, Ida Robertsen, Karsten Midtvedt, Stein Bergan, Jean Debord, Jean-Baptiste Woillard, Anders Åsberg, Rolf Anton Klaasen
Publikováno v:
Clinical and Translational Science
Therapeutic drug monitoring (TDM) is mandatory for the immunosuppressive drug tacrolimus (Tac). For clinical applicability, TDM is performed using morning trough concentrations. With recent developments making tacrolimus concentration determination p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc6b48c5df35d90d4038ebac81acf1fa
https://doi.org/10.1111/cts.12833
https://doi.org/10.1111/cts.12833
Autor:
Christine Berg Nordahl, Anders Mikal Andersen, Nils Tore Vethe, Kristine Hole, Rolf Anton Klaasen, Stein Bergan, Morten Skauby, Karsten Midtvedt, Sara Bremer
Publikováno v:
British Journal of Clinical Pharmacology
Aims To explore the pharmacodynamics of mycophenolic acid (MPA) through inosine monophosphate dehydrogenase (IMPDH) capacity measurement and purine levels in peripheral blood mononuclear cells (PBMC) longitudinally during the first year after renal t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a22202ab40cd4898c45d8176a46bea2a
https://doi.org/10.1111/bcp.14218
https://doi.org/10.1111/bcp.14218
Autor:
Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Johanna Elin Gehin, Øystein Sandanger, Inge Christoffer Olsen, Rolf Anton Klaasen, David John Warren, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm, Silje Watterdal Syversen
Background Anti-drug antibodies (ADAb) frequently form early in the treatment course of infliximab and other tumour necrosis factor (TNF) inhibitors, leading to treatment failure and adverse events. Objective To identify risk factors for ADAb in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb29427a0b28cd39dfac2c5335335f12
http://hdl.handle.net/10852/97708
http://hdl.handle.net/10852/97708
Autor:
Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Hammersbøen Bjørlykke, Joseph Sexton, Inge Christoffer Olsen, Johanna Elin Gehin, David John Warren, Rolf Anton Klaasen, Geir Noraberg, Trude Jannecke Bruun, Christian Kvikne Dotterud, Maud Kristine Aga Ljoså, Anne Julsrud Haugen, Rune Johan Njålla, Camilla Zettel, Carl Magnus Ystrøm, Yngvill Hovde Bragnes, Svanaug Skorpe, Turid Thune, Kathrine Aglen Seeberg, Brigitte Michelsen, Ingrid Marianne Blomgren, Eldri Kveine Strand, Pawel Mielnik, Roald Torp, Cato Mørk, Tore K. Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm
Publikováno v:
JAMA
IMPORTANCE: Proactive therapeutic drug monitoring (TDM), consisting of individualized treatment based on scheduled assessments of serum drug levels, has been proposed as an alternative to standard therapy to optimize efficacy and safety of infliximab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f19e319169617671a2db100d68ab77ac
https://europepmc.org/articles/PMC8693274/
https://europepmc.org/articles/PMC8693274/
Autor:
E. K. Strand, I. S. H. Hatten, Kathrine A. Seeberg, Knut E.A. Lundin, Rolf Anton Klaasen, Tore K Kvien, Knut Tveit, C. Mørk, Espen A Haavardsholm, S. S. Hoie, G. L. Goll, Gert Huppertz-Hauss, Jon Hagfors, A. Poyan, Synøve Kalstad, B. Gulbrandsen, Geir Noraberg, Jørgen Jahnsen, David J. Warren, K. Waksvik, K. Ryggen, H. U. Rashid, Cecilia Vold, Ingrid Prytz Berset, Øivind Asak, Nils Bolstad, S. O. Frigstad, Bjørg Tilde Svanes Fevang, Bjørn Moum, Ulf Prestegård, Joseph Sexton, C. C. Zettel, I. P. Midtgard, Magne Henriksen, Ingrid M. Blomgren, M. Lorentzen, Roald Torp, Carl Magnus Ystrøm, K. Skjetne, T. J. Bruun, Katrine Dvergsnes, Pawel Mielnik, J. Krogh, Ø. Brenna, Inge C. Olsen, Inger Marie Jensen Hansen, S. Baigh, K. K. Jørgensen
Publikováno v:
Journal of Internal Medicine
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that switching from infliximab originator to less expensive biosimilar CT-P13 was not inferior to continued treatment wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed2e54f175da6e1a1bd891ec3eb52816
https://doi.org/10.1111/joim.12880
https://doi.org/10.1111/joim.12880
Autor:
E.S. Norli, Rolf Anton Klaasen, Tore K Kvien, J. E. Gehin, M.D. Mjaavatten, G. L. Goll, Silje W Syversen, David J. Warren, Nils Bolstad, Trine Bjøro
Publikováno v:
Rheumatology International
The aim of the study was to assess RF cross-reactivity to animal antibodies used in immunoassays, and to test if selected commercial immunoassays are vulnerable to interference from RF, causing false test results. Our study included samples from pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dbf3d2e43b7421df9cd75339b7d8d16
http://hdl.handle.net/10852/92568
http://hdl.handle.net/10852/92568
Autor:
Nils Bolstad, Svanaug Skorpe, Yngvill Hovde Bragnes, Øystein Sandanger, Anne Julsrud Haugen, Roald Torp, Lars Normann Karlsen, Silje W Syversen, G. L. Goll, Ingrid M. Blomgren, David J. Warren, Camilla Zettel, Inge C. Olsen, Turid Thune, Christian Kvikne Dotterud, Brigitte Michelsen, Jørgen Jahnsen, Rune Johan Njålla, Geir Noraberg, K. K. Jørgensen, Pawel Mielnik, Carl Magnus Ystrøm, Kathrine A. Seeberg, J. E. Gehin, Joseph O. Sexton, Tore K Kvien, C. Mørk, Maud Kristine Aga Ljoså, Rolf Anton Klaasen, Trude Jannecke Bruun, Marthe Kirkesæther Brun, Espen A Haavardsholm, E. K. Strand
Publikováno v:
Journal of the American Medical Association (JAMA)
Importance Proactive therapeutic drug monitoring (TDM), defined as individualized drug dosing based on scheduled monitoring of serum drug levels, has been proposed as an alternative to standard therapy to maximize efficacy and safety of infliximab an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7427e8aee61a86b9681517c460490d0
https://hdl.handle.net/11250/3048675
https://hdl.handle.net/11250/3048675
Autor:
Øivind Asak, Nils Bolstad, Jon Florholmen, Jørgen Jahnsen, Inge C. Olsen, G. L. Goll, Kathrine A. Seeberg, Liv Sagatun, Geir Noraberg, Knut E.A. Lundin, David J. Warren, Cecilia Vold, Magne Henriksen, Ulf Prestegård, Joseph Sexton, Jon Hagfors, Jan Henrik Rydning, Ingrid M. Blomgren, Rolf Anton Klaasen, Katrine Dvergsnes, Kristin Kaasen Jørgensen, Carl Magnus Ystrøm, Tore K Kvien, Gert Huppertz-Hauss, Bjørn Moum, Ingrid Prytz Berset, Roald Torp, Svein Oskar Frigstad, Espen A Haavardsholm
Publikováno v:
BioDrugs
Biodrugs
Biodrugs
Background: TNF-alpha inhibitors have improved treatment of chronic immune-mediated inflammatory disorders. The NOR-SWITCH main and extension trial addressed switching from infliximab originator (IFX) to CT-P13 across six diseases. Here we present th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9abe8284e6a86f126777aa9b144edd9a
https://hdl.handle.net/11250/2683922
https://hdl.handle.net/11250/2683922